James Cassella
Chief Development Officer Trevi Therapeutics
Dr. James Cassella is Chief Development Officer at Trevi Therapeutics, where he leads clinical development strategy for investigational therapies targeting serious neurologically mediated conditions with unmet need, including chronic cough in idiopathic pulmonary fibrosis. With over 35 years of experience in CNS drug development, Dr. Cassella brings deep expertise in advancing novel therapies from early-stage research through global regulatory approvals. He previously served as CDO at Concert Pharmaceuticals, where he oversaw the successful development and approval of Leqselvi™ and played a key role in the company’s acquisition by Sun Pharma. Dr. Cassella holds a Ph.D. in Physiological Psychology from Dartmouth College and completed his postdoctoral work at Yale School of Medicine.
Seminars
- Exploring refractory chronic cough as a distinct clinical burden in IPF and ILDs: what are we missing in current trial designs?
- Is cough the “itch of the lung”? Drawing translational parallels between chronic cough and other hypersensitization syndromes like atopic dermatitis
- Mechanistic insights: The role of centrally acting, unscheduled opioid receptor modulators in treating IPF-related cough versus peripherally targeted approaches
- Clinical considerations in trial design, endpoint selection, and measuring meaningful improvement for patients living with IPF-related chronic cough
